Attendee search 

Brace Pharmaceuticals is based in Rockville, MD, and is a strategic investment company formed by Brazil-based pharma company EMS S/A. Brace investment structure varies depending on a company’s development stage; for early-stage opportunities Brace typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities Brace is more likely to form strategic partnerships that involve rights to an asset. Brace is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

Brace Pharmaceuticals invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities. Drug-device combinations will also be considered, but Brace does not invest in diagnostics. The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

Gordian Biotechnologies addressing the urgent unmet medical existing within antibiotic resistance by developing first-in-class reversible b-lactamase inhibitors that allow existing antibiotics to be effective against otherwise resistant pathogens. By combining an FDA approved antibiotic with our novel b-lactamase inhibitors, Gordian Biotechnologies  disarms the bacteria’s resistance mechanism, allowing the antibiotic to defeat the pathogen. 

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems. AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

AdvaMed 2015 - October 5-7, San Diego - is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems. AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

AdvaMed 2015 - October 5-7, San Diego - is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

Biosight, LLC  is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications

Westwood & Wilshire is a premier provider of executive search services to the Pharmaceutical, Biotechnology, Medical Devices and Diagnostics sectors.  Services include:

-Direct Hire Executive Search
-Interim Executive Search and Consultant Placement
-Board of Director and Advisory Group Development

Our clients range from Venture Capital-backed portfolio start ups to Fortune 500 Big Pharma. Our success encompasses executive level placements across Clinical, Medical, Regulatory, R&D, Quality and Commercial.

Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases.  We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.

Value Proposition

Pharma is looking for 3 key things:

1. Novel, never seen before, chemistry from new environments to fight chronic disease

2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects

3. New mechanisms of action to fight chronic disease in new and more effective manner

It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”.  Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation.  The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.  

We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.  

Best Regards,

Kurt Dieck

President and CEO

kdieck@biosortia.com

(614) 296-7076

5AM Ventures is an early-stage venture capital firm focused on building next-generation life science companies. The firm has offices in Menlo Park, CA and Waltham, MA. Formed by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands-on approach to company building.  In addition to leading investments and contributing as board members of its portfolio companies, 5AM is directly involved in company strategy, management recruiting, business development and fundraising and often takes on short-term operating roles.

The 5AM portfolio, built on advanced life science technologies, is diversified by two key categories: sector & type.  In the sector category, companies are diversified by innovative platform technologies, corporate spin-offs, and products with shorter development cycles.  In the type category, companies are diversified by product discovery, drug development, and medical technologies.

Longitude Capital is a private equity group founded in 2006 with offices in Menlo Park, California and Greenwich, Connecticut. The firm has $700 million in assets and has raised two funds, with the most recent fund closing at $385m in 2012. Longitude makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. Longitude Capital primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

Medtronic was founded in 1949 and is based in Minneapolis Minnesota. Medtronic makes strategic investments and acquisitions in the medical device sector and is focused on cardiovascular diseases diabetes diseases of the nervous system (including Parkinson's disease and dystonia) and musculoskeletal conditions. The firm has acquired a number of medical technology and biotechnology companies. Medtronic is also interested in orthopedic products sports health products and telehealth/connected medical devices (particularly consumer apps for health management). Medtronic also makes grants to non-profit organizations. Instructions on applying for investment or grants can be found at Innovate With Medtronic: http://www.medtronic.com/innovation/innovate-with-medtronic.html